LEONARD JOHN M sold $287K of NTLA

Intellia Therapeutics (NTLA) appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings extensive experience in rare disease therapies and will lead clinical development and regulatory affairs. The company is advancing its CRISPR gene editing pipeline, including Phase 3 trials for transthyretin amyloidosis.

ARK Innovation ETF, managed by Cathie Wood, bought $81M in Nvidia, $13.1M in Broadcom, and $7.3M in CoreWeave, while selling $111.1M in AMD. Other purchases included Intellia Therapeutics, BWX Technologies, and Tesla. Sales included 10x Genomics, Tempus AI, Alphabet, and Palantir.

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Intellia Therapeutics (NTLA) awaits FDA decision on lonvo-z for hereditary angioedema (HAE) on March 10, with Phase III data showing 87% attack-rate reduction. The company is preparing for commercial launch, though pricing is undecided. Intellia also advances its TTR amyloidosis study and reports $630M in cash, with a $300M debt facility for funding into 2028.

Intellia Therapeutics (NTLA) outlined a two-track strategy at the Morgan Stanley conference. The FDA accepted its biologics license application for lonvo-z, with a PDUFA date of March 10, 2025. The company reported strong HAE data, including an 87% reduction in attack rate. Intellia has $630M in cash and expects to fund operations into 2028. It is preparing a targeted launch for lonvo-z and is advancing its TTR amyloidosis program, which faces design and competitive questions.

Intellia Therapeutics (NTLA) secured a $400M credit facility with OrbiMed, drawing $75M initially. The remaining $325M is contingent on milestones. The facility has a 9.15% minimum interest rate. NTLA has $628.4M in cash but reported a $106.6M Q2 net loss. The financing supports potential U.S. launch of lonvo-z and other programs.